Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/7622
Citations | ||
Scopus | Web of ScienceĀ® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Harmatz, P. | - |
dc.contributor.author | Whitley, C. | - |
dc.contributor.author | Waber, L. | - |
dc.contributor.author | Pais, R. | - |
dc.contributor.author | Steiner, R. | - |
dc.contributor.author | Plecko, B. | - |
dc.contributor.author | Kaplan, P. | - |
dc.contributor.author | Simon, J. | - |
dc.contributor.author | Butensky, E. | - |
dc.contributor.author | Hopwood, J. | - |
dc.date.issued | 2004 | - |
dc.identifier.citation | Journal of Pediatrics, 2004; 144(5):574-580 | - |
dc.identifier.issn | 0022-3476 | - |
dc.identifier.issn | 1097-6833 | - |
dc.identifier.uri | http://hdl.handle.net/2440/7622 | - |
dc.description.abstract | <h4>Objectives</h4>To evaluate the safety and efficacy of weekly treatment with human recombinant N-acetylgalactosamine 4-sulfatase (rhASB) in humans with mucopolysaccharidosis type VI (MPS VI).<h4>Study design</h4>An ongoing Phase I/II, randomized, two-dose, double-blind study. Patients were randomized to weekly infusions of either high (1.0 mg/kg) or low (0.2 mg/kg) doses of rhASB. Six patients (3 male, 3 female; age 7-16 years) completed at least 24 weeks of treatment, five of this group have completed at least 48 weeks.<h4>Results</h4>No drug-related serious adverse events, significant laboratory abnormalities, or allergic reactions were observed in the study. The high-dose group experienced a more rapid and larger relative reduction in urinary glycosaminoglycan that was sustained through week 48. Improvements in the 6-minute walk test were observed in all patients with dramatic gains in those walking <100 meters at baseline. Shoulder range of motion improved in all patients at week 48 and joint pain improved in patients with significant pain at baseline.<h4>Conclusions</h4>rhASB treatment was well-tolerated and reduced lysosomal storage as evidenced by a dose-dependent reduction in urinary glycosaminoglycan. Clinical responses were present in all patients, but the largest gains occurred in patients with advanced disease receiving high-dose rhASB. | - |
dc.description.statementofresponsibility | Paul Harmatz, Chester B Whitley, Lewis Waber, Ray Pais, Robert Steiner, Barbara Plecko, Paige Kaplan, Julie Simon, Ellen Butensky, John J Hopwood | - |
dc.language.iso | en | - |
dc.publisher | Mosby Inc | - |
dc.source.uri | http://dx.doi.org/10.1016/j.jpeds.2004.03.018 | - |
dc.subject | Humans | - |
dc.subject | Mucopolysaccharidosis VI | - |
dc.subject | N-Acetylgalactosamine-4-Sulfatase | - |
dc.subject | Recombinant Proteins | - |
dc.subject | Statistics, Nonparametric | - |
dc.subject | Double-Blind Method | - |
dc.subject | Dose-Response Relationship, Drug | - |
dc.subject | Adolescent | - |
dc.subject | Child | - |
dc.subject | Female | - |
dc.subject | Male | - |
dc.title | Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome) | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1016/j.jpeds.2004.03.018 | - |
pubs.publication-status | Published | - |
Appears in Collections: | Aurora harvest 4 Paediatrics publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.